


Highlights of This Issue 1443

SMALL MOLECULE THERAPEUTICS


- 1445**  **U1 Adaptors Suppress the *KRAS*-*MYC* Oncogenic Axis in Human Pancreatic Cancer Xenografts**
Ashley T. Tsang, Crissy Dudgeon, Lan Yi, Xin Yu, Rafal Goraczniak, Kristen Donohue, Samuel Kogan, Mark A. Brenneman, Eric S. Ho, Samuel I. Gundersen, and Darren R. Carpizo
- 1456** **Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas**
Amanda R. King, Christopher D. Corso, Evan M. Chen, Eric Song, Paul Bongiorno, Zhe Chen, Ranjini K. Sundaram, Ranjit S. Bindra, and W. Mark Saltzman
- 1470**  **Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth *In Vitro* and *In Vivo* By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR**
Ranganayaki Muralidharan, Anish Babu, Narsireddy Amreddy, Akhil Srivastava, Allshine Chen, Yan Daniel Zhao, Uday B. Kompella, Anupama Munshi, and Rajagopal Ramesh
- 1487** **Photodynamic Therapy Using Photosensitizer-Encapsulated Polymeric Nanoparticle to Overcome ATP-Binding Cassette Transporter Subfamily G2 Function in Pancreatic Cancer**
Yoon Jin Roh, Ju Hee Kim, In-Wook Kim, Kun Na, Jae Myung Park, and Myung-Gyu Choi
- 1497**  **The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34⁺ Stem/Progenitor Cells**
Maximilien Murone, Ramin Radpour, Antoine Attinger, Anne Vaslin Chessex, Anne-Laure Huguenin, Christian M. Schürch, Yara Banz, Saumitra Sengupta, Michel Aguet, Stefania Rigotti, Yogeshwar Bachhav, Frédéric Massière, Murali Ramachandra, Andres McAllister, and Carsten Riether
- 1511** **Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors**
Lloyd T. Lam, Xiaoyu Lin, Emily J. Faivre, Ziping Yang, Xiaoli Huang, Denise M. Wilcox, Richard J. Bellin, Sha Jin, Stephen K. Tahir, Michael Mitten, Terry Magoc, Anahita Bhathena, Warren M. Kati, Daniel H. Albert, Yu Shen, and Tamar Uziel
- 1521** **Nicosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer**
Chengfei Liu, Cameron M. Armstrong, Wei Lou, Alan P. Lombard, Vito Cucchiara, Xinwei Gu, Joy C. Yang, Nagalakshmi Nadiminty, Chong-xian Pan, Christopher P. Evans, and Allen C. Gao
- 1531**  **Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3**
Chuan Xing Wu, Aimin Xu, Cathy C. Zhang, Peter Olson, Lin Chen, Terence K. Lee, Tan To Cheung, Chung Mau Lo, and Xiao Qi Wang
- 1544**  **Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma**
Jian-Yang Ao, Xiao-Dong Zhu, Zong-Tao Chai, Hao Cai, Yuan-Yuan Zhang, Ke-Zhi Zhang, Ling-Qun Kong, Ning Zhang, Bo-Gen Ye, De-Ning Ma, and Hui-Chuan Sun
- 1555**  **Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs**
Mark A. Currier, Justine R. Stehn, Ashleigh Swain, Duo Chen, Jeff Hook, Eleanor Eiffe, Andrew Heaton, David Brown, Brooke A. Nartker, David W. Eaves, Nina Kloss, Herbert Treutlein, Jun Zeng, Irina B. Alieva, Vera B. Dugina, Edna C. Hardeman, Peter W. Gunning, and Timothy P. Cripe
- 1566** ***In Vivo* Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models**
Jasmien Cornillie, Agnieszka Wozniak, Peter Pokreisz, Andrea Casazza, Lise Vreys, Jasmien Wellens, Ulla Vanleeuw, Yemarshet K. Gebreyohannes, Maria Debiec-Rychter, Raf Sciot, Daphne Hompes, and Patrick Schöffski

Table of Contents

LARGE MOLECULE THERAPEUTICS

- 1576**  **Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4**
Jay Harper, Christopher Lloyd, Nazzareno Dimasi, Dorin Toader, Rose Marwood, Leeanne Lewis, David Bannister, Jelena Jovanovic, Ryan Fleming, Francois D'Hooge, Shenlan Mao, Allison M. Marrero, Martin Korade III, Patrick Strout, Linda Xu, Cui Chen, Leslie Wetzel, Shannon Breen, Lilian van Vlerken-Ysla, Sanjoo Jalla, Marlon Rebelatto, Haihong Zhong, Elaine M. Hurt, Mary Jane Hinrichs, Keven Huang, Philip W. Howard, David A. Tice, Robert E. Hollingsworth, Ronald Herbst, and Adeela Kamal
- 1588** **Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis**
Sheng Zhang, Fei Liang, Ji Zhu, and Qiang Chen

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 1596**  **Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non–Small Cell Lung Cancer Cells**
Kayleigh C. Ross, Andrew J. Andrews, Christopher D. Marion, Timothy J. Yen, and Vikram Bhattacharjee
- 1610** **Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma**
Clare E. Weeden, Aliaksei Z. Holik, Richard J. Young, Stephen B. Ma, Jean-Marc Garnier, Stephen B. Fox, Phillip Antippa, Louis B. Irving, Daniel P. Steinfert, Gavin M. Wright, Prudence A. Russell, Matthew E. Ritchie, Christopher J. Burns, Benjamin Solomon, and Marie-Liesse Asselin-Labat
- 1623** **Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/ MAPK Signaling**
Sarah K. Nelson-Taylor, Anh T. Le, Minjae Yoo, Laura Schubert, Katie M. Mishall, Andrea Doak, Marileila Varella-Garcia, Aik-Choon Tan, and Robert C. Doebele




- 1634** **Sensitization of EGFR Wild-Type Non–Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib**
Judith Raimbourg, Marie-Pierre Joalland, Mathilde Cabart, Ludmilla de Plater, Fanny Bouquet, Ariel Savina, Didier Decaudin, Jaafar Bennouna, François M. Vallette, and Lisenn Lalier
- 1645** **JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines**
Kian Kani, Carolina Garri, Katrin Tiemann, Paymaneh D. Malihi, Vasu Punj, Anthony L. Nguyen, Janet Lee, Lindsey D. Hughes, Ruth M. Alvarez, Damien M. Wood, Ah Young Joo, Jonathan E. Katz, David B. Agus, and Parag Mallick
- 1658** **Reactivation of the p90RSK–CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G₂–M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC**
Suman Chatterjee, Eric H.-B. Huang, Ian Christie, and Timothy F. Burns
- 1669**  **Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia**
Carly T. Campbell, Jessica N. Haladyna, David A. Drubin, Ty M. Thomson, Michael J. Maria, Taylor Yamauchi, Nigel J. Waters, Edward J. Olhava, Roy M. Pollock, Jesse J. Smith, Robert A. Copeland, Stephen J. Blakemore, Kathrin M. Bernt, and Scott R. Daigle
- 1680** **Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth**
Jacob Kach, Tiha M. Long, Phillip Selman, Eva Y. Tonsing-Carter, Maria A. Bacalao, Ricardo R. Lastra, Larischa de Wet, Shane Comiskey, Marc Gillard, Calvin VanOpstall, Diana C. West, Wen-Ching Chan, Donald Vander Griend, Suzanne D. Conzen, and Russell Z. Szmulewitz
- 1693** **Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis**
Jonathan Cooper, Qingwen Xu, Lu Zhou, Milica Pavlovic, Virginia Ojeda, Kamalika Moulick, Elisa de Stanchina, John T. Poirier, Marjorie Zauderer, Charles M. Rudin, Matthias A. Karajannis, C. Oliver Hanemann, and Filippo G. Giancotti

Table of Contents

- 1705** **Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and *In Vivo* Tumor Growth**
Argyris Spyrou, Soumi Kundu, Lulu Haseeb, Di Yu, Tommie Olofsson, Keith Dredge, Edward Hammond, Uri Barash, Israel Vlodavsky, and Karin Forsberg-Nilsson


COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 1717** **Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib**
 Jayaprakash D. Karkera, Gabriela Martinez Cardona, Katherine Bell, Dana Gaffney, Joseph C. Portale, Ademi Santiago-Walker, Christopher H. Moy, Peter King, Michael Sharp, Rastislav Bahleda, Feng R. Luo, John D. Alvarez, Matthew V. Lorenzi, and Suso J. Platero

 **AC icon indicates AuthorChoice**
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover illustrates PEG-PLA polymer nanoparticle (red) distribution within the brain parenchyma after local infusion into the rat striatum. A single infusion of 20 μ l volume is able to cover a significant region of the caudate putamen. One of the major challenges of brain tumor therapy is getting therapeutically relevant concentrations of drugs into the brain, and keeping those levels high for a prolonged period. King and Corso et al. show that this can be accomplished with a combination of convection enhanced delivery and nanoparticle systems (see p. 1456 for further discussion). By loading a radiosensitizing agent into the delivery vehicles and slowly releasing the agent over many days, they show significant survival benefits in a syngeneic rat tumor model.



Molecular Cancer Therapeutics

16 (8)

Mol Cancer Ther 2017;16:1443-1726.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/16/8>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/16/8>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.